Lantheus Holdings, Inc. (LNTH) Stock
LNTH Key Statistics
About Lantheus Holdings, Inc.
Lantheus Holdings, Inc. is a global pharmaceutical company dedicated to the development, manufacturing, and commercialization of advanced diagnostic and therapeutic agents. Their mission is to empower clinicians worldwide in the accurate diagnosis and effective treatment of a wide spectrum of conditions, particularly heart disease, various cancers, and other serious illnesses. Their current diagnostic portfolio features several key products: DEFINITY, a microbubble ultrasound contrast agent for cardiac evaluations; TechneLite, a technetium generator essential for nuclear medicine; Xenon-133, used to assess pulmonary function; Neurolite, which helps identify stroke-damaged areas in the brain; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 for detecting cardiovascular disease; and Gallium-67, utilized in identifying infections and cancerous tumors. They also offer the Automated Bone Scan Index, a tool for quantifying prostate cancer burden from bone scans; PYLARIFY, designed for visualizing lymph nodes, bone, and soft tissue metastases to detect recurrent or metastatic prostate cancer; and Cobalt (Co 57), a non-pharmaceutical radiochemical. In the therapeutic space, Lantheus provides AZEDRA, a radiopharmaceutical treatment for both adult and pediatric patients, and RELISTOR, a medication addressing opioid-induced constipation. The company's robust development pipeline includes promising innovations such as flurpiridaz F 18, an agent for assessing myocardial blood flow; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in both children and adults; PYLARIFY AI, an AI-powered medical device software for standardized quantitative analysis of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. Lantheus serves a diverse client base, including radiopharmacies, distributors, integrated delivery networks, hospitals, clinics, and group medical practices. They foster strategic collaborations with notable industry partners such as NanoMab Technology Limited, Bausch Health Companies, Inc., GE Healthcare Limited, Curium, Bayer AG, CytoDyn Inc., ROTOP, FUJIFILM, Regeneron Pharmaceuticals, Inc., and POINT Biopharma US Inc. Established in 1956, Lantheus Holdings, Inc. maintains its corporate headquarters in North Billerica, Massachusetts.
CEO: Mary Anne Heino. Company website
LNTH — Frequently Asked Questions
What is the LNTH stock price today?
Lantheus Holdings, Inc. (LNTH) trades at $100.55, down 0.25% on the day, as of Sep 20, 2026 15:00 UTC.
What is Lantheus Holdings, Inc.'s market cap?
Lantheus Holdings, Inc. has a market capitalisation of $6.55B, calculated from the live LNTH share price and shares outstanding.
What is the P/E ratio of LNTH?
LNTH trades at a trailing P/E of 24.29, from earnings per share of $4.14 over the last twelve months.
How much revenue does Lantheus Holdings, Inc. make?
Lantheus Holdings, Inc. generated revenue of $1.56B over the trailing twelve months, which puts the stock at 4.21 times sales.
What is the 52-week range for LNTH?
LNTH has traded between $49.67 and $111.86 over the past 52 weeks, and the last price is 10.1% below that high.
Is Lantheus Holdings, Inc. profitable?
Yes. Lantheus Holdings, Inc. keeps 17.69% of revenue as net income over the trailing twelve months.
What is the analyst price target for LNTH?
Wall Street analysts rate LNTH Buy, with an average price target of $105.27, 4.7% above the current price.
What sector is Lantheus Holdings, Inc. in?
Lantheus Holdings, Inc. is classified under the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry, and is domiciled in US.
Who is the CEO of Lantheus Holdings, Inc.?
Mary Anne Heino is the chief executive of Lantheus Holdings, Inc., which employs 1,193 people.
Where can I track LNTH in real time?
QFI Terminal shows LNTH with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See LNTH live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open LNTH in Terminal See plans